Search

Your search keyword '"Fasanaro, Elena"' showing total 31 results
Start Over Author "Fasanaro, Elena"
31 results on '"Fasanaro, Elena"'

5. Role of SAMITAL in the Prevention and Treatment of Chemo-Radiotherapy-Induced Oral Mucositis in Head and Neck Carcinoma: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (ROSAM)

Author

Fasanaro, Elena, primary, Del Bianco, Paola, additional, Groff, Elena, additional, Riva, Antonella, additional, Petrangolini, Giovanna, additional, Busato, Fabio, additional, Stritoni, Paola, additional, Scarzello, Giovanni, additional, Loreggian, Lucio, additional, and De Salvo, Gian Luca, additional

Published
2022
Full Text
View/download PDF

14. Individual Radiosensitivity in Oncological Patients: Linking Adverse Normal Tissue Reactions and Genetic Features

Author

Palumbo, Elisa, primary, Piotto, Celeste, additional, Calura, Enrica, additional, Fasanaro, Elena, additional, Groff, Elena, additional, Busato, Fabio, additional, El Khouzai, Badr, additional, Rigo, Michele, additional, Baggio, Laura, additional, Romualdi, Chiara, additional, Zafiropoulos, Demetre, additional, Russo, Antonella, additional, Mognato, Maddalena, additional, and Corti, Luigi, additional

Published
2019
Full Text
View/download PDF

19. Nuclear nonmetastatic protein 23-H1 expression and epithelial-mesenchymal transition in laryngeal carcinoma: A pilot investigation

Author

Marioni, Gino, primary, Cappellesso, Rocco, additional, Ottaviano, Giancarlo, additional, Fasanaro, Elena, additional, Marchese-Ragona, Rosario, additional, Favaretto, Niccolò, additional, Giacomelli, Luciano, additional, Guzzardo, Vincenza, additional, Martini, Alessandro, additional, Fassina, Ambrogio, additional, and Blandamura, Stella, additional

Published
2018
Full Text
View/download PDF

20. Yap, Taz and Areg Expression in Eighth Cranial Nerve Schwannoma

Author

Martini, Alessandro, primary, Marioni, Gino, additional, Zanoletti, Elisabetta, additional, Cappellesso, Rocco, additional, Stramare, Roberto, additional, Fasanaro, Elena, additional, Faccioli, Chiara, additional, Giacomelli, Luciano, additional, Denaro, Luca, additional, D'Avella, Domenico, additional, Mazzoni, Antonio, additional, and Fassina, Ambrogio, additional

Published
2017
Full Text
View/download PDF

21. Cortactin and phosphorylated cortactin tyr421 and tyr466 expression in supraglottic laryngeal carcinomas and lymph node metastases

Author

Marioni, Gino, primary, Lionello, Marco, additional, Marchese-Ragona, Rosario, additional, Fasanaro, Elena, additional, Valentini, Elisa, additional, Zanoletti, Elisabetta, additional, Stritoni, Paola, additional, Ramacciotti, Giulia, additional, Guzzardo, Vincenza, additional, Giacomelli, Luciano, additional, Ralli, Giovanni, additional, Ottaviano, Giancarlo, additional, and Blandamura, Stella, additional

Published
2017
Full Text
View/download PDF

25. Cortactin and phosphorylated cortactin tyr421and tyr466expression in supraglottic laryngeal carcinomas and lymph node metastases

Author

Marioni, Gino, Lionello, Marco, Marchese-Ragona, Rosario, Fasanaro, Elena, Valentini, Elisa, Zanoletti, Elisabetta, Stritoni, Paola, Ramacciotti, Giulia, Guzzardo, Vincenza, Giacomelli, Luciano, Ralli, Giovanni, Ottaviano, Giancarlo, and Blandamura, Stella

Abstract

Background: The most important adverse prognostic factor for laryngeal squamous cell carcinoma (LSCC) is the presence of cervical lymph node metastases. The supraglottic area of the larynx is richly supplied with lymphatics, and 25%-75% of supraglottic carcinomas metastasize in neck lymph nodes. Cortactin is a multidomain protein related to actin cytoskeleton regulation, podosome and lamellipodia formation, integrin signaling, axon guidance and extracellular matrix degradation. Cortactin is involved in metastasis formation because of its role in cell mobility. The present study focused mainly on the role of cortactin and phosphorylated cortactin (residues tyr421and tyr466) expression and subcellular localization in primary supraglottic LSCCs and their cervical lymph node metastases.Methods: The immunohistochemical expression of cortactin, p-Y466-cortactin and p-Y421-cortactin was assessed in 38 primary supraglottic LSCCs and 10 lymph node metastases. The statistical approach included bootstrapping analysis.Results: Despite a significantly higher expression of cortactin in carcinoma cells than in adjacent normal laryngeal mucosa, no associations emerged between prognosis and the expression of cortactin or its isoforms in supraglottic LSCC. Statistical analysis found cortactin expression higher in less-differentiated LSCCs (p = 0.03). A significant direct correlation was found between cortactin and p-Y466-cortactin levels (p = 0.031), and between p-Y466-cortactin and p-Y421-cortactin levels (p = 0.001).Conclusions: Cortactin expression in carcinoma cells and its known involvement in the EGFR pathway suggest a role for this protein as a target for LSCC therapy. Further prospective studies are needed to investigate the potential of cortactin, p-Y466-cortactin and p-Y421-cortactin expression as markers of response to treatment (particularly EGFR-directed agents) in LSCC.

Published
2018
Full Text
View/download PDF

26. OP091

Author

Fasanaro, Elena, primary, Lovato, Andrea, additional, Blandamura, Stella, additional, Bernardi, Elena, additional, Val, Matteo, additional, Staffieri, Alberto, additional, and Marioni, Gino, additional

Published
2013
Full Text
View/download PDF

30. Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis.

Author

Franz L, Alessandrini L, Ottaviano G, di Carlo R, Fasanaro E, Ramacciotti G, Contro G, and Marioni G

Subjects
Adult, Aged, Biomarkers, Tumor metabolism, Carcinoma, Squamous Cell metabolism, Cohort Studies, Disease-Free Survival, Female, Humans, Laryngeal Neoplasms diagnosis, Laryngeal Neoplasms pathology, Lymphocytes, Tumor-Infiltrating metabolism, Lymphocytes, Tumor-Infiltrating pathology, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Prognosis, B7-H1 Antigen metabolism, Carcinoma, Squamous Cell pathology, Laryngeal Neoplasms metabolism, Neoplasm Recurrence, Local metabolism, Tumor Microenvironment immunology
Abstract

Background: The prognostic role of programmed death-ligand 1 (PD-L1) expression and the tumor's immune microenvironment has yet to be investigated in the specific setting of adjuvant postoperative radiotherapy (PORT) for laryngeal carcinoma (LSCC). The main aim of this exploratory study was to investigate, also by cluster analysis, whether PD-L1 expression (in terms of combined positive score [CPS]), tumor-infiltrating lymphocytes (TIL), and tertiary lymphoid structures (TLS) correlated prognostically with response to PORT in a cohort of consecutive LSCC patients., Methods: PD-L1, TIL and TLS were assessed in 24 consecutive patients with LSCC who underwent PORT. Cluster analysis was used to classify cases on the strength of these parameters., Results: A CPS ≥ 1 was associated with a significantly lower recurrence rate (p = 0.033), and longer disease-free survival (DFS) (p = 0.012) than a CPS < 1. Two clusters of prognostic relevance emerged from our analysis. Cluster 1 was characterized by a mean CPS of 23.0 ± 37.9, a mean TIL count of 68.0 ± 16.4, and the presence of TLS in all cases. Cluster 2 featured a mean CPS of 3.1 ± 7.3, a mean TIL count of 23.9 ± 16.5, and no cases with TLS. Cluster 1 showed a trend towards a lower recurrence rate (p = 0.071) and longer DFS (p = 0.054) than cluster 2., Conclusions: Judging from this preliminary investigation, assessing PD-L1 and immune microenvironment markers seems a promising approach for identifying patients at higher risk of LSCC recurrence after PORT, who might reasonably benefit from adjuvant postoperative chemo-RT, or immunotherapy., (Copyright © 2020 Elsevier GmbH. All rights reserved.)

Published
2020
Full Text
View/download PDF

31. Cortactin and phosphorylated cortactin tyr 421 and tyr 466 expression in supraglottic laryngeal carcinomas and lymph node metastases.

Author

Marioni G, Lionello M, Marchese-Ragona R, Fasanaro E, Valentini E, Zanoletti E, Stritoni P, Ramacciotti G, Guzzardo V, Giacomelli L, Ralli G, Ottaviano G, and Blandamura S

Subjects
Adult, Aged, Biomarkers, Tumor genetics, Carcinoma pathology, Female, Gene Expression Regulation, Neoplastic, Humans, Laryngeal Neoplasms pathology, Lymph Nodes pathology, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Phosphorylation, Prognosis, Carcinoma genetics, Cortactin genetics, ErbB Receptors genetics, Laryngeal Neoplasms genetics
Abstract

Background: The most important adverse prognostic factor for laryngeal squamous cell carcinoma (LSCC) is the presence of cervical lymph node metastases. The supraglottic area of the larynx is richly supplied with lymphatics, and 25%-75% of supraglottic carcinomas metastasize in neck lymph nodes. Cortactin is a multidomain protein related to actin cytoskeleton regulation, podosome and lamellipodia formation, integrin signaling, axon guidance and extracellular matrix degradation. Cortactin is involved in metastasis formation because of its role in cell mobility. The present study focused mainly on the role of cortactin and phosphorylated cortactin (residues tyr 421 and tyr 466 ) expression and subcellular localization in primary supraglottic LSCCs and their cervical lymph node metastases., Methods: The immunohistochemical expression of cortactin, p-Y466-cortactin and p-Y421-cortactin was assessed in 38 primary supraglottic LSCCs and 10 lymph node metastases. The statistical approach included bootstrapping analysis., Results: Despite a significantly higher expression of cortactin in carcinoma cells than in adjacent normal laryngeal mucosa, no associations emerged between prognosis and the expression of cortactin or its isoforms in supraglottic LSCC. Statistical analysis found cortactin expression higher in less-differentiated LSCCs (p = 0.03). A significant direct correlation was found between cortactin and p-Y466-cortactin levels (p = 0.031), and between p-Y466-cortactin and p-Y421-cortactin levels (p = 0.001)., Conclusions: Cortactin expression in carcinoma cells and its known involvement in the EGFR pathway suggest a role for this protein as a target for LSCC therapy. Further prospective studies are needed to investigate the potential of cortactin, p-Y466-cortactin and p-Y421-cortactin expression as markers of response to treatment (particularly EGFR-directed agents) in LSCC.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results